quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:00:00·364d
PRRelease
Interpace Biosciences, Inc. logo

Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

IDXG· Interpace Biosciences, Inc.
Health Care
Original source

Companies

  • IDXG
    Interpace Biosciences, Inc.
    Health Care

Recent analyst ratings

  • Nov 17UpdateHC Wainwright & Co.-

Related

  • SEC22d
    Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • SEC24d
    SEC Form 10-K filed by Interpace Biosciences, Inc.
  • PR24d
    Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results
  • INSIDER65d
    Large owner 1315 Capital Ii, L.P. converted options into 9,405,941 shares (SEC Form 4)
  • INSIDER78d
    Large owner Ampersand 2018 Limited Partnership converted options into 13,861,386 shares (SEC Form 4)
  • SEC93d
    Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
  • SEC141d
    Interpace Biosciences, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • SEC162d
    Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022